Mondaq Canada: Food, Drugs, Healthcare, Life Sciences
Norton Rose Fulbright Canada LLP
The Federal Court established the parameters to calculate Teva Canada Limited's damages for being delayed from entering the olanzapine market, clarified evidentiary issues on fact witnesses and hearsay...
Norton Rose Fulbright Canada LLP
On April 13th, the federal Liberal government tabled the much anticipated Cannabis Act. While many recreational marijuana users now have reason to rejoice, employers across the country are left with unanswered questions as to how the upcoming legalization will affect the workplace.
Cassels Brock
Today the federal government released Bill C-45, the draft Cannabis Act. If enacted, this will make Canada the first G7 country to legalize recreational cannabis.
Norton Rose Fulbright Canada LLP
In the 2015 Federal election, the Liberal Party of Canada ran on a platform that included the legalization of recreational cannabis.
Duane Morris LLP
Last week, in a both exciting and sobering press release, Canada announced a plan to fully "legalize, strictly regulate and restrict access" to cannabis in the Great White North. The release starts bluntly: "The current approach to cannabis does not work."
Norton Rose Fulbright Canada LLP
The Federal Court dismissed Apotex's application for judicial review of the Minister of Health's (Minister's) decision to require additional information from Apotex as part of its Notice of Compliance (NOC) submissions for certain drugs manufactured in India by Apotex affiliates.
Torys LLP
On March 10, Health Canada released a white paper entitled "Public Release of Clinical Information in Drug Submissions and Medical Device Applications."
Norton Rose Fulbright Canada LLP
Health Canada released the white paper – Public Release of Clinical Information in Drug Submissions and Medical Device Applications.
Blake, Cassels & Graydon LLP
The end of 2016 brought with it some good news for the defence in respect of pharmaceutical class actions, including a successful defence verdict in the first pharmaceutical product liability common issues trial in Canada.
Gardiner Roberts LLP
In 2016, the College of Chiropractors of Ontario (CCO) made a number of revisions to its By-Law 17: Public Register...
WeirFoulds LLP
Prime Minister Justin Trudeau's Liberal government plans on introducing legislation in early April 2017 with the intention of legalizing recreational marijuana by July 1, 2018.
Norton Rose Fulbright Canada LLP
While certain sectors experienced a shaky 2016 with respect to M&A activity, deal activity in the pharmaceutical and biotechnology industries held steady following record levels in 2015...
Bennett Jones LLP
In this edition of our series on the Task Force's final report "A Framework for the Legalization and Regulation of Cannabis in Canada" (the "Report") we explore the Task Force's recommendations...
Blake, Cassels & Graydon LLP
Personal information protection and compliance with privacy laws have taken centre stage with life sciences companies as a result of the increasing use of data in connection with a myriad of products...
McCarthy Tétrault LLP
In a recent case out of Goderich, Ontario a $20,000 fine, the highest of its kind in Canada, was handed out for a health privacy violation.
Norton Rose Fulbright Canada LLP
The Federal Court dismissed Bristol-Myers Squibb's prohibition application, finding that one of the patents had an overarching promise and lacked utility, and the other patent was "obvious to try." The court also assessed double patenting at the priority date of the later filed patent.
Howie, Sacks & Henry
You take a deep breath, give a good blow to the fluffy head and watch as the seeds float around and spread everywhere.
Norton Rose Fulbright Canada LLP
Teva asked the Court of Appeal (FCA) to overturn the Federal Court's findings (reported here) on utility and insufficiency of disclosure.
Miller Thomson LLP
There is an exception for facilities that only provide counselling or referrals for these procedures.
Norton Rose Fulbright Canada LLP
This is Apotex's third application relating to data integrity concerns with its Indian affiliates.
Latest Video
Most Popular Recent Articles
Cassels Brock
A Licensed Producer (LP) can obtain a permit from the federal Minister of Health to export cannabis internationally from Canada to a single and specified importer.
McInnes Cooper
But employers need to nip cannabis in the workplace in the bud by acting now to be prepared for cannabis legalization when it happens.
Stewart McKelvey
In my December 15, 2016 article, Federal Government's Cannabis Report: What does it mean for employers?, I noted the Report's1 suggestion that there was a lack of research to reliably determine when individuals are impaired by cannabis.
Minden Gross LLP
Matt Maurer and Whitney Abrams published their article on a case where the Nova Scotia Human Rights Board ordered an employee insurance plan to cover medical marijuana expenses.
Norton Rose Fulbright Canada LLP
The Federal Court dismissed Bristol-Myers Squibb's prohibition application, finding that one of the patents had an overarching promise and lacked utility, and the other patent was "obvious to try." The court also assessed double patenting at the priority date of the later filed patent.
Howie, Sacks & Henry
In this blog post, I review Monsanto's role in continuing to market Roundup as a safe substance while evidence mounts to the contrary.
Bennett Jones LLP
In this edition of our series on the Task Force's final report "A Framework for the Legalization and Regulation of Cannabis in Canada" (the "Report") we explore the Task Force's recommendations...
Cassels Brock
In Apotex Inc. v Canada (Minister of Health) ("Apotex"), the Federal Court (the "Court") provided some guidance with respect to the procedure pharmaceutical companies should undertake...
Lerners
PP and DD were set up by a mutual friend in the spring of 2014. They dated for several weeks, during which time PP understood that DD was using birth control and did not intend to conceive a child.
Norton Rose Fulbright Canada LLP
The Canadian Parliament recently passed Bill S-201, the Genetic Non-Discrimination Act, which protects individuals from having to disclose information related to genetic testing and test results.
Article Search Using Filters
Related Topics
Mondaq Advice Centre (MACs)
Popular Authors
Popular Contributors
Up-coming Events Search
Tools
Font Size:
Translation
Channels
Mondaq on Twitter
Partners
In association with